IHD

 A

Here are 3 key points from the Scientific American article on inflammation and heart disease:

---

1. Inflammation is a major driver of heart disease

Research shows heart disease is not just about cholesterol buildup — it also involves chronic inflammation in artery walls, which helps trigger plaque formation and heart attacks. (Scientific American)

---

2. Immune activity can worsen arterial damage

When LDL cholesterol enters artery walls, it triggers an immune response:

• white blood cells enter the artery

• inflammatory signals build up

• plaques become unstable and can rupture, causing heart attacks (Scientific American)

---

3. Anti-inflammatory drugs can reduce risk in some patients

Clinical trials (like those targeting inflammatory pathways such as IL-1β) show that reducing inflammation can lower heart attack and stroke risk, even without directly lowering cholesterol. (Scientific American)

---

TAGLINE

Heart disease isn’t just blocked arteries — it’s also a chronic inflammatory immune process, and targeting inflammation may help prevent heart attacks.

A

Here are the main drugs mentioned or used in this anti-inflammatory approach to heart disease:

---

1. Canakinumab

• A monoclonal antibody that blocks interleukin-1β (IL-1β), a key inflammation signal

• Tested in the large CANTOS trial

• Shown to reduce heart attacks in some patients without lowering cholesterol

---

2. Colchicine

• Traditionally used for gout

• Works by reducing broad inflammatory activity

• Low-dose colchicine has been shown to lower risk of cardiovascular events in some studies

---

3. Methotrexate (tested but not effective here)

• A common anti-inflammatory drug used in rheumatoid arthritis

• Studied in heart disease, but large trials showed no clear benefit for preventing heart attacks

---

TAGLINE

Targeting inflammation in heart disease has led to real drug breakthroughs like canakinumab and colchicine, showing heart attacks are partly an immune-driven process.